News
ACRS
1.170
-4.10%
-0.050
Press Release: Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer. Dr. Manion brings over two decades of experience in pharmaceutical research and development. The company is targeting transcription factors to discover precision medicines for cancer and other diseases.
Dow Jones · 1d ago
ACLARIS THERAPEUTICS INC - MANION SUCCEEDS INTERIM CEO ABBIE CELNIKER WHO WILL CONTINUE TO SERVE AS CHAIR OF COMPANY'S BOARD OF DIRECTORS
Reuters · 1d ago
Weekly Report: what happened at ACRS last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at ACRS last week (0408-0412)?
Weekly Report · 04/15 09:11
Weekly Report: what happened at ACRS last week (0401-0405)?
Weekly Report · 04/08 09:12
Weekly Report: what happened at ACRS last week (0325-0329)?
Weekly Report · 04/01 09:12
Weekly Report: what happened at ACRS last week (0318-0322)?
Weekly Report · 03/25 09:12
Board Changes Ahead of Aclaris Therapeutics Annual Meeting
TipRanks · 03/19 20:43
Weekly Report: what happened at ACRS last week (0311-0315)?
Weekly Report · 03/18 09:12
Biotech's Role in Addressing the Pancreatic Cancer Emergency
Pancreatic cancer still has the highest mortality rate of all major cancers. American Cancer Society projecting a record year for new cancer cases in 2024. Researchers and the biotech sector are working diligently to improve the chances of those diagnosed with pancreatic cancer. Researchers at the Mayo Clinic made a discovery that advances knowledge of how the cancer spreads.
Barchart · 03/14 07:45
Weekly Report: what happened at ACRS last week (0304-0308)?
Weekly Report · 03/11 09:12
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up
Aclaris Therapeutics, Inc. Shares have gained 25% in the last 30 days. The company's price-to-sales ratio of 3.3x is within range of the Pharmaceuticals industry median. But the company has been growing revenue less than most other companies lately. Revenue is anticipated to slump by 32% per year over the next three years.
Simply Wall St · 03/07 11:05
Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying
Dow Jones index closed lower by over 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Recent notable insider transactions for penny stocks include Aclaris Therapeutics, Lumen Technologies and Personalis.
Benzinga · 03/06 11:56
Aclaris Therapeutics Inc: Statement of changes in beneficial ownership of securities
Press release · 03/06 08:00
Aclaris (ACRS) Upgraded to Buy: Here's Why
NASDAQ · 03/04 17:00
Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB), Aethlon Medical (AEMD) and Aclaris Therapeutics (ACRS)
TipRanks · 03/04 11:31
Aclaris Therapeutics: Cautious Hold Rating Amid Financial Stability and Pipeline Potential
TipRanks · 03/04 11:30
Weekly Report: what happened at ACRS last week (0226-0301)?
Weekly Report · 03/04 09:12
Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) just released its latest full-year results. Revenues of US$31m exceeded analyst forecasts by 70% and statutory losses were smaller than expected. The analysts have revised down their revenue estimates for the company for 2024. The consensus price target for the business has fallen to US$6.17 per share. This implies a 75% reduction in the company's expected revenues.
Simply Wall St · 03/01 11:48
More
Webull provides a variety of real-time ACRS stock news. You can receive the latest news about Aclaris Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.